| March 2007 |
| Cover Story |
Clinical Trials |
Industry In Figures |
PHARMA 40 2007
co-chairs of the Bill & Melinda Gates Foundation, Bill
and Melinda Gates have control of a fund of $31.9 billion.
One of the foundation’s core missions is to tackle deadly
diseases such as malaria and tuberculosis. With this kind
of spending power and their determination to drive up
global healthcare provision, the Gates’ influence on the
pharma industry is unquestionable. more... |
HOPE FOR KIDNEY CANCER TREATMENT
Sutent, a new kidney cancer drug, was given early
approval by the eMeA in January 2006. Pfizer’s
Dr Charles Baum tells James Drury that this rapid
development was the result of a good collaborative
relationship and strong trial results. more... |
GLOBAL REBALANCE
Murray Aitken of IMS Health looks back on a year of shifting dynamics within the global
pharmaceutical market and reveals the key trends that will shape the industry in the year ahead. more... |
| IT & Data Management |
Contract Services |
Packaging |
KNOWLEDGE-DRIVEN SUCCESS
Success in the life sciences industry is increasingly determined by access to information. Microsoft’s
Paul Mattes explains how breaking down information barriers is the key to breakthrough drug development.
more... |
FUNDING THROUGH PARTNERSHIPS
By adding value through strategic partnerships, new business
models are changing the way the industry prioritises licensing
and collaboration. Louise Makin, CEO of BTG, explores this
strategy and explains how it has helped accelerate the
development of BTG’s compounds. more... |
TOUCH TO COMMUNICATE
Braille is used on pharmaceutical packaging and patient information to meet the needs of blind and partially sighted
people, however, legislation has proved to be a minefield. Tony Harper, chairman of the BSI Braille Panel, provides an
in-depth look at the problems encountered by the industry and some likely solutions. more...
|
| Raw Materials |
Regional Focus |
Drug Discovery |
TROUBLE WITH TRUST
he public places great confidence in the pharmaceutical industry.
An individual has a reasonable expectation in the safety and performance
of any product bought over the counter. But while the public believes in the
products they use, socMA president Joseph Acker takes a less indulgent view. more...
|
DON'T RULE OUT BRITANIA
The UK has a successful history in the field of pharma and biotechnology, but its recent progress in drug discovery
and new medicines has been surpassed by the Far East and the rest of Europe. Dr Richard Barker, ABPI director
general, tells James Drury why he believes the country is still an attractive investment for world pharma. more...
|
NEW HORIZONS IN
THERMODYNAMIC DECOMPOSITION
Going against much of the current received wisdom in the
field, Professor Steve Homans proposes thermodynamic
decomposition as an aid to optimising ligand affinity. more... |
| Supply Chain Management |
|
Logistics |
COLLABORATE TO GENERATE
The world of medicine is constantly changing and pharma companies need to be innovative to
ensure continued growth. Forming an alliance is one solution, and a well-designed partnering
strategy is essential for success, writes Peter Hug, Roche Pharma Partnering. more...
|
DEADLY TRADE
the global counterfeit drugs market is stronger than ever and poses a great risk to public health worldwide. nic Paton asks dr Jonathan Harper, and andrew Jackson of novartis what governments, regulatory bodies and the pharma industry are doing to stop this dangerous fraud. more...
|
A SIMPLE ANSWER TO
COLD CHAIN CHAOS
Pharmaceutical manufacturers and distributors are coming under a barrage of stringent
regulations when faced with the challenges of cold chain distribution. While the pharma industry
is well regulated, there is some confusion when it comes to the shipment of goods worldwide.
Fortunately, Rafik Bishara is working towards a standardised set of global guidelines.more... |
